Actualités sur Health

28.02.2013 – 08:01
Shire Pharmaceuticals Group Plc
Shire Supports Rare Disease Day 2013
Lexington, Massachusetts (ots/PRNewswire) - - Global Initiatives Underscore Company's Long-Term Commitment to the Rare Disease Community Shire plc today announced its support of Rare Disease Day, joining patients, healthcare providers, and patient organizations around the world to support a day that focuses attention on rare diseases as a public health issue, and highlights the need for more understanding and awareness ...
plus
26.02.2013 – 07:07
LifeWatch AG
EANS-Adhoc: LifeWatch AG / Fourth Quarter 2012 and Full Fiscal Year 2012 Results confirm successful turnaround (with document)
http://resources.euroadhoc.com/us/E2sWCuEm http://resources.euroadhoc.com/us/1Vsl1JqX http://resources.euroadhoc.com/us/xjnZF0tD http://resources.euroadhoc.com/us/pfwE96bs issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: ...
2 Documents
plus
25.02.2013 – 07:00
Sanofi
Sanofi Demonstrates Commitment to Innovative Diabetes Care at International Diabetes Technology Conference
Paris, France (ots) - - Data presented at ATTD by Sanofi will focus on the company's integrated portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery and contributions to advancing diabetes research - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its comprehensive portfolio of ...
plus
22.02.2013 – 14:22
Lupin Ltd
Lupin Receives FDA Approval for New Drug Application for SUPRAX® Oral Suspension, 500 mg/5mL
Mumbai, India And Baltimore (ots/PRNewswire) - Approval to add to growing SUPRAX(R) Franchise Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence ...
plus
22.02.2013 – 13:02
Sanofi Pasteur MSD GmbH
European Medicines Agency Recommends Approval of Hexyon 6-in-1 Paediatric Vaccine
Lyon, France (ots/PRNewswire) - Upon approval Hexyon will be the only fully liquid, ready-to-use 6-in-1 paediatric vaccine in Europe Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that their innovative 6-in-1 paediatric vaccine Hexyon has been recommended for marketing authorisation by the European Medicines Agency's ...
plus
20.02.2013 – 01:12
Mundipharma International
Phase 3 Data Published in The Lancet Show Bendamustine (Levact®) Plus Rituximab Doubles Progression-Free Survival in Patients With Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Compared With CHOP-R
Cambridge, England (ots/PRNewswire) - NOT INTENDED FOR MEDIA IN THE NETHERLANDS -Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; ...
plus

19.02.2013 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch to report on Fourth Quarter and Full Fiscal Year 2012 Results on February 26, 2013 (with document)
http://resources.euroadhoc.com/us/WuYAhdmi http://resources.euroadhoc.com/us/zIy1Ktwc issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
2 Documents
plus
11.02.2013 – 13:55
Cardiorentis
Cardiorentis initiates first-ever acute heart failure Phase III clinical trial designed to assess early treatment on cardiovascular mortality and symptoms
Zug, Switzerland (ots/PRNewswire) - Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide's Efficacy and safety in patients with Acute Heart Failure) aims to ...
plus
08.02.2013 – 14:01
Shire Pharmaceuticals Group Plc
Shire and Impax Settle Litigation Concerning Supply of Adderall XR Authorized Generic
Philadelphia (ots/PRNewswire) - Shire plc , announces that its subsidiary, Shire LLC, has settled all pending litigation with Impax Laboratories, Inc. ("Impax") over Shire's supply of an authorized generic version of Adderall XR. Shire has been supplying Impax with authorized generic Adderall XR since October 2009 pursuant to a supply agreement between the parties. In ...
plus
06.02.2013 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch AG / LifeWatch to report on Fourth Quarter and Full Fiscal Year 2012 Results on February 26, 2013 (with document)
http://resources.euroadhoc.com/us/Ojrskc2e http://resources.euroadhoc.com/us/YxkzoEfd issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
2 Documents
plus
06.02.2013 – 17:31
Daiichi Sankyo Europe GmbH
European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
Munich (ots/PRNewswire) - The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality[1] Daiichi Sankyo Europe GmbH announced the enrolment of the first ...
plus
04.02.2013 – 09:06
Sanofi Diabetes
Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe
Paris (ots/PRNewswire) - - Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist - Sanofi announced today that the European Commission has granted Marketing Authorisation in Europe for Lyxumia(R) (lixisenatide). Lyxumia(R), the first once-daily prandial GLP-1 receptor agonist, is ...
plus

30.01.2013 – 13:10
European Commission
Dedicated EU Journalist Prize on Smoking Shines Spotlight on European Commission's Anti-tobacco Campaign "Ex-Smokers are Unstoppable"
Brussels (ots/PRNewswire) - The winners of the EU Health Prize for Journalists were announced at an awards ceremony in Brussels yesterday evening. German journalist, Tobias Zick received the prestigious special prize for articles on smoking. Zick, writing for NEON magazine was celebrated for his in-depth article ...
plus
23.01.2013 – 17:35
LifeWatch AG
EANS-Adhoc: LifeWatch AG / Extraordinary General Meeting of LifeWatch AG (with document)
http://resources.euroadhoc.com/us/E53tdyIt issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Un document
plus
15.01.2013 – 15:32
Biocartis
Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology
Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...
plus
14.01.2013 – 08:02
Sanofi Pasteur MSD GmbH
Sanofi Pasteur MSD's Andrea Rappagliosi Appointed President of Vaccines Europe
Lyon, France (ots/PRNewswire) - Appointment marks new chapter in vaccine advocacy in Europe Andrea Rappagliosi, Vice President of Market Access, Health Policy & Medical Affairs at Sanofi Pasteur MSD has been appointed President of Vaccines Europe as of 1st January 2013. Vaccines Europe is the group representing vaccine manufacturers within the European Federation of ...
plus
11.01.2013 – 10:28
Astellas Pharma Europe Limited
New Class of Treatment for Overactive Bladder Approved in Europe
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
plus
08.01.2013 – 13:01
Shire Pharmaceuticals Group Plc
Shire Acquires Lotus Tissue Repair, Inc.
Lexington, Massachusetts (ots/PRNewswire) - - HGT Pipeline Enhanced with Protein Replacement Therapy Being Investigated for the Treatment of Dystrophic Epidermolysis Bullosa Shire plc , announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the ...
plus

07.01.2013 – 01:02
Eisai Europe Limited
New First-in-class Treatment Fycompa® Launches in Norway for Most Common Form of Epilepsy
Hatfield, England (ots/PRNewswire) - Eisai today launches Fycompa(R) (perampanel) in Norway as a treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first in an entirely new class of treatment for uncontrolled partial epilepsy, the most common form of the ...
plus
03.01.2013 – 16:10
Merck Serono
Merck Serono Announces FDA Approval of Rebif® Rebidose® (interferon beta-1a)
Geneva (ots/PRNewswire) - Merck Serono, a division of Merck, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) approved Rebif(R) Rebidose(R) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). "Over the past two decades, ...
plus
02.01.2013 – 07:01
Eisai Europe Limited
Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain
Hatfield, England (ots/PRNewswire) - Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan ...
plus
19.12.2012 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch receives the "Indian Certificate" for its LifeWatch V health smartphone (with document)
http://resources.euroadhoc.com/us/IPI4rsuU issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open ...
plus
19.12.2012 – 06:02
Allergan, Inc.
Allergan's BOTOX® (botulinum toxin type A) Receives a Positive Opinion in Fourteen European Countries for Idiopathic Overactive Bladder
Marlow, England (ots/PRNewswire) - Data demonstrates BOTOX(R)injections can reduce urinary leakage episodes for up to six months in patients who have had an inadequate response to, or are intolerant of, anticholinergic medication Today, Allergan Inc. announced that BOTOX(R)has received a positive opinion from the ...
plus
18.12.2012 – 17:36
LifeWatch AG
EANS-Adhoc: Invitation to the Extraordinary General Meeting of Shareholders of LifeWatch Ltd., Neuhausen am Rheinfall on January 23, 2013 at 02:00 p.m. CET (doors open at 01:30 p.m.) at the Zurich Marriott Hotel, Neumühlequai 42, 8001 ...
http://resources.euroadhoc.com/us/KN1K9flc issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus

18.12.2012 – 15:18
Shire Pharmaceuticals Group Plc
Positive Response from European Regulatory Procedure Supports Approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD
Nyon, Switzerland (ots/PRNewswire) - Shire plc today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children ...
plus
18.12.2012 – 08:03
Norgine GmbH
Norgine and SpePharm Holding Enter Into Joint Venture
Amsterdam (ots/PRNewswire) - Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene(R), MuGard(R), Xerotin(R), PROther(R) and the Dantrium(R) brands. The new joint venture will ...
plus
13.12.2012 – 11:23
Johnson & Johnson and Janssen
CellSearch® 'Liquid Biopsy' Approved for Breast Cancer Patients in China
Raritan, New Jersey (ots/PRNewswire) - Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch(R) circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch(R) the first and only approved CTC test for cancer patients in China, which is the seventh ...
plus
12.12.2012 – 14:07
Biocartis
Biocartis Completes ?34,5 Million ($44,5 Million) Series D Fund Raising
Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...
plus
07.12.2012 – 17:59
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries
Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...
plus
07.12.2012 – 08:02
Alfa Wassermann/Norgine
XIFAXAN® 550mg (rifaximin-?) Registered for Reduction of Recurrence of Episodes of Overt Hepatic Encephalopathy in the EU*
Bologna, Italy And Amsterdam (ots/PRNewswire) - Alfa Wassermann and Norgine are pleased to announce that they have received European Marketing Authorisation for XIFAXAN(R) 550mg (rifaximin-alpha) / REFERO(R) / TARGAXAN(R) / TIXTELLER(R) in the reduction of recurrence of episodes of overt hepatic encephalopathy (HE) ...
plus

Précédent51525354555657585960Suivant